Skip to main content




Dual-antibody drugs effective against COVID-19 variants in animal study

Dual-antibody drugs effective against COVID-19 variants in animal study

Colorized scanning electron micrograph of an apoptotic cell (red) infected with SARS-COV-2 virus particles (yellow), also known as novel coronavirus, isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. (Photo: NIH/Handout via REUTERS)

LONDON: COVID-19 therapies made from a cocktail of two types of antibodies were effective against a wide range of variants of the coronavirus in a mice and hamster study, the Washington University School of Medicine in St Louis reported on Monday (Jun 21).

Antibodies are used to treat cases of COVID-19, often early in the process. Former US President Donald Trump was treated by an antibody cocktail by Regeneron Pharmaceuticals in October after he tested positive for COVID-19.

The latest study included three of the four variants that have been designated "variants of concern" by the World Health Organization, including Alpha, first identified in the UK, Beta, first found in South Africa and Gamma found in Brazil, as well as an emerging variant from India similar to the Delta variant of concern.

The US Food and Drug Administration in April revoked the emergency use authorisation of Eli Lilly's single antibody therapy, bamlanivimab, saying there was increased circulation of variants resistant to the therapy when used alone.

Other studies have previously shown that some antibody combination therapies remained potent against those emerging variants of the coronavirus that were resistant to single antibody therapies.

The latest study found that combinations of two antibodies often retained potency against variants even when one of the two antibodies lost some or all ability to neutralise the variant in lab studies.

The study, which was conducted in mice and hamsters, tested all single and combination antibody therapies authorised for emergency use by the FDA against emerging international and US variants of the virus.

The researchers evaluated the FDA authorised combination therapies made by Regeneron, Eli Lilly and a single antibody therapy, sotrovimab, by Vir Biotechnology Inc and GlaxoSmithKline.

They also assessed the antibodies currently in clinical trials by AbbVie, Vir and AstraZeneca.

"Resistance arose with some of the monotherapies, but never with combination therapy," study co-author Jacco Boon wrote.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: Reuters/ec


Also worth reading